The DOI matches its Crossref record; the references it cites are not checked yet.
The endless frontier? The recent increase of R&D productivity in pharmaceuticals
Open accessPublished version of a preprint
Abstract
Background: Studies on the early 2000s documented increasing attrition rates and duration of clinical trials, leading to a representation of a “productivity crisis” in pharmaceutical research and development (R&D). In this paper, we produce a new set of analyses for the last decade and report a recent increase of R&D productivity within the industry. Methods: We use an extensive data set on the development history of more than 50,000 projects between 1990 and 2017, which we integrate with data on sales, patents, and anagraphical information on each institution involved. We devise an indicator to quantify the novelty of each project, based on its set of mechanisms of action. Results: First, we investigate how R&D projects are allocated across therapeutic areas and find a polarization towards high uncertainty/high potential reward indications, with a strong focus on oncology. Second, we find that attrition rates have been decreasing at all stages of clinical research in recent years. In parallel, for each phase, we observe a significant reduction of time required to identify projects to be discontinued. Moreover, our analysis shows that more recent successful R&D projects are increasingly based on novel mechanisms of action and target novel indications, which are characterized by relatively small patient populations. Third, we find that the number of R&D projects on advanced therapies is also growing. Finally, we investigate the relative contribution to productivity variations of different types of institutions along the drug development process, with a specific focus on the distinction between the roles of Originators and Developers of R&D projects. We document that in the last decade Originator–Developer collaborations in which biotech companies act as Developers have been growing in importance. Moreover, we show that biotechnology companies have reached levels of productivity in project development that are equivalent to those of large pharmaceutical companies. Conclusions: Our study reports on the state of R&D productivity in the bio-pharmaceutical industry, finding several signals of an improving performance, with R&D projects becoming more targeted and novel in terms of indications and mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 a Time evolution of attrition rates at different stages of drug development. Black circles: data; red solid lines: linear regression in the corresponding time window; blue vertical solid line: changepoint. In a given year, the attrition rate for each development phase is defined as the percentage of projects that started the phase in that year and failed to pass to the subsequent phase within 4 years (accordingly, 2013 is the last year we do consider). b Average (± standard deviation) yearly phase-by-phase attrition rates in three different time intervals (1990–1999, 2000–2009, 2010–2013). We also report the significance level of a Wilcoxon rank sum test [25] on the difference of attrition rates in 2000–2009 and 2010–2013](https://figures.cochat.ai/paper-figures/16ac1cdb29ff408eb3527d5323d33f14/the-endless-frontier-the-recent-increase-of-r-amp-d-productivity-in-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“prior studies in drug development have reported that only 7.6% to 12.3% of preclinical candidates advance to Phase I clinical trials23, with higher estimates of up to 24.2% observed in oncology settings with strong academia-industry collaboration24.”
From A quantitative analysis of global AI medical studies: gaps in randomized controlled trials (2026) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 55 · Cited by 77
Research works printed but not linked: 2
- Chial H. DNA sequencing technologies key to the human genome project. Nat Educ. 2008;1(1):219.
- OECD. Global action to drive innovation in alzheimer’s disease and other dementias: connecting research, regulation and access. OECD Science, Technology and Industry Policy Papers, vol. 31. 2016.
Metadata
- Authors
- Pammolli, F., Righetto, L., Abrignani, S., Pani, L., Pelicci, P. G., & Rabosio, E.
- Affiliations
- Human Technopole (IT)
- University of Milan (IT)
- University of Modena and Reggio Emilia (IT)
- European Institute of Oncology (IT)
- Corresponding author
- Righetto, Lorenzo
- Abrignani, Sergio
- Pani, Luca
- Pelicci, Pier Giuseppe
- Rabosio, Emanuele
- Venue
- Journal of Translational Medicine
- Published
- 2020-04-09
- Volume
- 18
- Issue
- 1
- Pages
- 162-162
- ISSN
- 1479-5876 (ISSN-L)
- PMC
- PMC7147016
- OpenAlex
- W3015388949
- Cited by
- 77
- References
- 55
- Citations by year
- 2026: 11 · 2025: 11 · 2024: 10 · 2023: 13 · 2022: 11 · 2021: 15 · 2020: 6
- FWCI
- 9.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Journal of Translational Medicine (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Firm Innovation and Growth
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- attrition rates, clinical trial duration, mechanism of action, anticancer drug development, small patient populations, advanced therapies, biotechnology companies, pharmaceutical industry, drug development
- MeSH terms
- Drug Industry, Pharmaceutical Preparations, Humans, Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The endless frontier? The recent increase of R&D productivity in pharmaceuticals. https://app.cochat.ai/papers/10.1186/s12967-020-02313-z
- The paper
- Pammolli, F., Righetto, L., Abrignani, S., Pani, L., Pelicci, P. G., & Rabosio, E. (2020). The endless frontier? The recent increase of R&D productivity in pharmaceuticals. Journal of Translational Medicine. https://doi.org/10.1186/s12967-020-02313-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.